PMA device
Multi-Target Stool DNA (mtsDNA) Test, Cologuard Plus
Exact Sciences Corporation · System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection (PHP, Class III) · First FDA decision Oct 3, 2024, newest Oct 3, 2024Colorectal cancer and polyps
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
1
Naming "Multi-Target Stool DNA"
MAUDE reports
0
Brand "Multi-Target Stool DNA", since 2015
PubMed studies
111
Mentioning "Multi-Target Stool DNA"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Multi-Target Stool DNA (mtsDNA) Test, Cologuard Plus
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P230043 · Decided Oct 3, 2024 · 286 days after receipt
Device type: System, colorectal neoplasia, DNA methylation and hemoglobin detection (PHP) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39276CGS Administrators, LLCUpdated Feb 13, 2026
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39262Noridian Healthcare Solutions, LLCUpdated Jan 12, 2026
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39256Palmetto GBAUpdated Mar 4, 2025
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39356WPS Insurance CorporationUpdated Feb 20, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "Multi-Target Stool DNA", any status and sponsor, newest update first.
- Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and MortalityActive, not recruiting
Exact Sciences CorporationNot on our public-company list
NCT04124406 · 150,000 participants (planned) · Start Oct 18, 2019 · Primary completion Dec 31, 2023
Device: Cologuard · For: Colon Cancer
Sites: Rochester, Minnesota
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Multi-Target Stool DNA", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PHP
33 reports: 20 malfunction, 10 injury, 1 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Multi-Target Stool DNA"[tiab]. The summary above synthesizes these.
- Inappropriate Multi-Target Stool DNA Use for Colorectal Cancer Screening: Risks, Compliance, and Outcomes.
Lazar NJ, Khreisat A, AlKloub R, et al. · Cureus · 2023
- Optimal Strategies for Colorectal Cancer Screening.
Jain S, Maque J, Galoosian A, et al. · Curr Treat Options Oncol · 2022Review, Research Support, Non-U.S. Gov't
- Neoplasia Diagnosis After Multi-target Stool DNA Is Enhanced Among Lowest Baseline Detectors.
Ebner DW, Burger KN, Mahoney DW, et al. · Dig Dis Sci · 2023Research Support, N.I.H., Extramural
- Next-generation Multi-target Stool DNA Panel Accurately Detects Colorectal Cancer and Advanced Precancerous Lesions.
Gagrat ZD, Krockenberger M, Bhattacharya A, et al. · Cancer Prev Res (Phila) · 2024
- Fecal microbial biomarkers combined with multi-target stool DNA test improve diagnostic accuracy for colorectal cancer.
Fan JQ, Zhao WF, Lu QW, et al. · World J Gastrointest Oncol · 2023
- Adherence to multi-target stool DNA testing for colorectal cancer screening in the United States.
Le QA, Greene M, Gohil S, et al. · Int J Colorectal Dis · 2025
- Multi-Target Stool DNA and the Fecal Immunochemical Test: A Systematic Review and Meta-Analysis on Test Performances.
Ebner DW, Johnson HA, Estes C, et al. · Am J Prev Med · 2025Systematic Review, Meta-Analysis
- Detection of Postcolonoscopy Colorectal Neoplasia by Multi-target Stool DNA.
Ebner DW, Eckmann JD, Burger KN, et al. · Clin Transl Gastroenterol · 2021Research Support, N.I.H., Extramural
- Multi-Target Stool DNA Test: Is the Future Here?
Sweetser S, Ahlquist DA · Curr Gastroenterol Rep · 2016Review
- Three-Year Interval for the Multi-Target Stool DNA Test for Colorectal Cancer Screening: A Longitudinal Study.
Imperiale TF, Lavin PT, Marti TN, et al. · Cancer Prev Res (Phila) · 2023Research Support, Non-U.S. Gov't
- Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study.
Klepp P, Kisiel JB, Småstuen MC, et al. · Scand J Gastroenterol · 2018Evaluation Study
- The impact of multi-target stool DNA testing in clinical practice in the United States: A real-world evidence retrospective study.
Miller-Wilson LA, Limburg P, Helmueller L, et al. · Prev Med Rep · 2022
Other devices of this type
Also filed under product code PHP.
- CologuardExact Sciences Corporation · PMA 2024
- ShieldGuardant Health, Inc. · PMA 2026
- Epi proColonNew Day Diagnostics, LLC · PMA 2016
- SimpleScreen CRCFreenome, LLC · PMA 2026
- ColoHealthNew Day Diagnostics, LLC · PMA 2025
- Cologuard Stool DNA-Based Colorectal Cancer Screening TestExact Sciences Corporation · PMA 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.